This article is more than 5 years old. Information may no longer be current.
ANIKA gains CE mark approval for injectable treatment for chronic lateral epicondylosis
Click Here to Manage Email Alerts
Anika Therapeutics Inc. recently announced it has received CE mark approval for Orthovisc-T, a sodium hyaluronate for peritendinous injection, which is indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis.
Orthovisc-T is administered by injection and is designed to provide lubrication to the site of damaged tendons, which promotes tendon gliding and supports tendon repair, according to a company press release.
“We are excited to announce the timely European approval of Orthovisc-T for the treatment of pain associated with one of the most common overuse injuries to connective tissues, the condition commonly described as tennis elbow,” Charles H. Sherwood, PhD, president and chief executive officer of Anika Therapeutics Inc., said in the release. “The availability of Orthovisc-T not only promises to help millions of people in Europe find relief from this painful condition, it also expands our global foothold in orthopaedic medicine and provides real-world clinical experience to inform our path towards regulatory submission in the [United States] U.S.”
Orthovisc-T is the latest addition to Anika’s product portfolio, which includes Hyalofast, a biodegradable, hyaluronic acid-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects. Hyalofast and Orthovisc-T are both CE-marked and are pending regulatory submission in the United States.
Reference: